These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32215583)

  • 1. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
    Dess RT; Sun Y; Jackson WC; Jairath NK; Kishan AU; Wallington DG; Mahal BA; Stish BJ; Zumsteg ZS; Den RB; Hall WA; Gharzai LA; Jaworski EM; Reichert ZR; Morgan TM; Mehra R; Schaeffer EM; Sartor O; Nguyen PL; Lee WR; Rosenthal SA; Michalski JM; Schipper MJ; Dignam JJ; Pisansky TM; Zietman AL; Sandler HM; Efstathiou JA; Feng FY; Shipley WU; Spratt DE
    JAMA Oncol; 2020 May; 6(5):735-743. PubMed ID: 32215583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial.
    Tran PT; Lowe K; Tsai HL; Song DY; Hung AY; Hearn JWD; Miller S; Proudfoot JA; Deek MP; Phillips R; Lotan T; Paller CJ; Marshall CH; Markowski M; Dipasquale S; Denmeade S; Carducci M; Eisenberger M; DeWeese TL; Orton M; Deville C; Davicioni E; Liauw SL; Heath EI; Greco S; Desai NB; Spratt DE; Feng F; Wang H; Beer TM; Antonarakis ES
    J Clin Oncol; 2023 Feb; 41(6):1307-1317. PubMed ID: 36367998
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.
    Feng FY; Huang HC; Spratt DE; Zhao SG; Sandler HM; Simko JP; Davicioni E; Nguyen PL; Pollack A; Efstathiou JA; Dicker AP; Todorovic T; Margrave J; Liu YS; Dabbas B; Thompson DJS; Das R; Dignam JJ; Sweeney C; Attard G; Bahary JP; Lukka HR; Hall WA; Pisansky TM; Shah AB; Pugh SL; Shipley WU; Tran PT
    JAMA Oncol; 2021 Apr; 7(4):544-552. PubMed ID: 33570548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.
    Shipley WU; Seiferheld W; Lukka HR; Major PP; Heney NM; Grignon DJ; Sartor O; Patel MP; Bahary JP; Zietman AL; Pisansky TM; Zeitzer KL; Lawton CA; Feng FY; Lovett RD; Balogh AG; Souhami L; Rosenthal SA; Kerlin KJ; Dignam JJ; Pugh SL; Sandler HM;
    N Engl J Med; 2017 Feb; 376(5):417-428. PubMed ID: 28146658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.
    Stish BJ; Pisansky TM; Harmsen WS; Davis BJ; Tzou KS; Choo R; Buskirk SJ
    J Clin Oncol; 2016 Nov; 34(32):3864-3871. PubMed ID: 27480153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrating Prostate-specific Antigen Kinetics into Contemporary Predictive Nomograms of Salvage Radiotherapy After Radical Prostatectomy.
    Campbell SR; Tom MC; Agrawal S; Efstathiou JA; Michalski JM; Abramowitz MC; Pollack A; Spratt DE; Hearn JWD; Stephans KL; Gao T; Li J; Tendulkar RD
    Eur Urol Oncol; 2022 Jun; 5(3):304-313. PubMed ID: 34016556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA).
    Kapoor R; Deek MP; McIntyre R; Raman N; Kummerlowe M; Chen I; Gaver M; Wang H; Denmeade S; Lotan T; Paller C; Markowski M; Carducci M; Eisenberger M; Beer TM; Song DY; DeWeese TL; Hearn JW; Greco S; DeVille C; Desai NB; Heath EI; Liauw S; Spratt DE; Hung AY; Antonarakis ES; Tran PT
    BMC Cancer; 2019 Jun; 19(1):572. PubMed ID: 31196032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of salvage radiotherapy initiation at PSA ≤ 0.5 ng/ml on metastasis-free survival in patients with relapsed prostate cancer following prostatectomy.
    Lee EE; Singh T; Hu C; Han M; Deville CJ; Halthore A; Greco S; Tran P; DeWeese T; Song DY
    Prostate; 2023 Feb; 83(2):190-197. PubMed ID: 36316967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer.
    Kishan AU; Tendulkar RD; Tran PT; Parker CC; Nguyen PL; Stephenson AJ; Carrie C
    Eur Urol Oncol; 2018 May; 1(1):3-18. PubMed ID: 31100226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Androgen Therapy Overcomes the Time Delay in Initiation of Salvage Radiation Therapy and Rescues the Oncological Outcomes in Men with Recurrent Prostate Cancer After Radical Prostatectomy: A Post Hoc Analysis of the RTOG-9601 Trial Data.
    Sood A; Keeley J; Palma-Zamora I; Chien M; Corsi N; Jeong W; Rogers CG; Trinh QD; Peabody JO; Menon M; Abdollah F
    Ann Surg Oncol; 2022 Oct; 29(11):7206-7215. PubMed ID: 35608801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results.
    Ost P; Lumen N; Goessaert AS; Fonteyne V; De Troyer B; Jacobs F; De Meerleer G
    Eur Urol; 2011 Oct; 60(4):842-9. PubMed ID: 21514039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
    Kabarriti R; Ohri N; Hannan R; Tishbi N; Baliga S; McGovern KP; Mourad WF; Ghavamian R; Kalnicki S; Guha C; Garg MK
    Pract Radiat Oncol; 2014; 4(6):409-14. PubMed ID: 25407863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy.
    Lee SU; Cho KH; Kim JH; Kim YS; Nam TK; Kim JS; Cho J; Choi SH; Shim SJ; Kim JH; Chang AR
    Technol Cancer Res Treat; 2021; 20():15330338211041212. PubMed ID: 34806469
    [No Abstract]   [Full Text] [Related]  

  • 18. The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    Roberts MJ; Conduit C; Davis ID; Effeney RM; Williams S; Martin JM; Hofman MS; Hruby G; Eapen R; Gianacas C; Papa N; Lourenço RA; Dhillon HM; Allen R; Fontela A; Kaur B; Emmett L;
    BJU Int; 2024 Feb; 133 Suppl 3():39-47. PubMed ID: 37604702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?
    Tay KJ; Polascik TJ; Howard LE; Salama JK; Schulman AA; Chen Z; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Clin Genitourin Cancer; 2019 Oct; 17(5):e930-e938. PubMed ID: 31257075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment Outcomes from
    Emmett L; van Leeuwen PJ; Nandurkar R; Scheltema MJ; Cusick T; Hruby G; Kneebone A; Eade T; Fogarty G; Jagavkar R; Nguyen Q; Ho B; Joshua AM; Stricker P
    J Nucl Med; 2017 Dec; 58(12):1972-1976. PubMed ID: 28747524
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.